-
1.发明授权COMBINATION OF AKT INHIBITOR COMPOUND AND VEMURAFENIB FOR USE IN THERAPEUTIC TREATMENTS 有权AKT缓蚀剂复合物与VEMURAFENIB联合用于治疗性治疗
公开(公告)号：EP2694485B1
公开(公告)日：2017-11-15
申请号：EP12765234.5
申请日：2012-03-30
申请人： Genentech, Inc.
发明人： HOEFLICH, Klaus , MERCHANT, Mark
IPC分类号： C07D239/70 , A61K31/496
CPC分类号： A61K31/517 , A61K31/138 , A61K31/282 , A61K31/337 , A61K31/4166 , A61K31/4188 , A61K31/436 , A61K31/437 , A61K31/4745 , A61K31/495 , A61K31/496 , A61K31/513 , A61K31/519 , A61K31/555 , A61K31/58 , A61K31/704 , A61K31/7068 , A61K39/3955 , A61K2039/505 , C07D239/70 , C07D403/12 , C07K16/40 , A61K2300/00
-
公开(公告)号：EP3370775A1
公开(公告)日：2018-09-12
申请号：EP16805576.2
申请日：2016-11-03
IPC分类号： A61K45/06 , A61K31/4523 , A61K31/496 , A61P35/00
CPC分类号： A61K31/4523 , A61K31/496 , A61K45/06 , A61K2300/00 , A61P35/02
摘要： The present invention is directed to a combination therapy involving a selective Bcl-2 inhibitor and a MEK inhibitor for the treatment of a patient in need of such a therapy. The patient in need of the combination therapy is suffering from cancer, such as acute myeloid leukemia.
-
3.发明公开COMBINATIONS OF AKT INHIBITOR COMPOUNDS AND VEMURAFENIB, AND METHODS OF USE 有权AKT抑制剂化合物与VEMURAFENIB的组合以及使用方法
公开(公告)号：EP2694485A1
公开(公告)日：2014-02-12
申请号：EP12765234.5
申请日：2012-03-30
申请人： Genentech, Inc.
发明人： HOEFLICH, Klaus , MERCHANT, Mark
IPC分类号： C07D239/70 , A61K31/496
CPC分类号： A61K31/517 , A61K31/138 , A61K31/282 , A61K31/337 , A61K31/4166 , A61K31/4188 , A61K31/436 , A61K31/437 , A61K31/4745 , A61K31/495 , A61K31/496 , A61K31/513 , A61K31/519 , A61K31/555 , A61K31/58 , A61K31/704 , A61K31/7068 , A61K39/3955 , A61K2039/505 , C07D239/70 , C07D403/12 , C07K16/40 , A61K2300/00
摘要： The invention provides a combination of a) a compound of Formula Ia: [insert Formula Ia], or a pharmaceutically acceptable salt thereof, and b) vemurafenib or a pharmaceutically acceptable salt thereof for the prophylactic or therapeutic treatment of a hyperproliferative disorder, such as cancer.
摘要翻译： 本发明提供了a）式Ia化合物：[插入式Ia]或其药学上可接受的盐，和b）威罗菲尼或其药学上可接受的盐用于预防性或治疗性治疗过度增殖性病症的组合，所述过度增殖性病症例如 癌症。
-
公开(公告)号：EP2344543A2
公开(公告)日：2011-07-20
申请号：EP09740235.8
申请日：2009-10-14
发明人： BENDER, Brendan C. , EPPLER, Steve , HEGDE, Priti , JUMBE, Nelson L. , MERCHANT, Mark , PETERSON, Amy C. , REYES, Arthur E. II , XIANG, Hong
CPC分类号： C07K16/2863 , A61K39/39558 , A61K2039/505 , A61K2039/507 , A61K2039/545 , C07K16/32 , C07K2317/73 , C07K2317/76 , A61K2300/00
摘要： The present invention relates generally to the fields of molecular biology and growth factor regulation. More specifically, the invention relates to therapies for the treatment of pathological conditions, such as cancer.
-
公开(公告)号：EP2257293A2
公开(公告)日：2010-12-08
申请号：EP09716498.2
申请日：2009-03-06
申请人： Genentech, Inc.
IPC分类号： A61K31/517 , A61K39/395 , A61K45/06 , A61P35/00
CPC分类号： A61K31/517 , A61K31/5377 , A61K39/395 , A61K39/3955 , A61K39/39558 , A61K45/06 , A61K2039/505 , C12N15/1135 , C12N2310/122 , C12N2320/31 , A61K2300/00
摘要： The present invention relates generally to the fields of molecular biology and growth factor regulation. More specifically, the invention relates to combination therapies for the treatment of pathological conditions, such as cancer comprising a c-met antagonist and a EGFR antagonist.
-
-
-
-
搜索结果
5 条记录 (耗时 0.025 秒)
